Vanguard amends Schedule 13G/A for Repligen (RGEN): reports 0 shares
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 7 to Schedule 13G/A reporting no beneficial ownership of Repligen Corp common stock. The filing states 0 shares beneficially owned, representing 0% of the class, and shows zero voting and dispositive power. The amendment notes an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report ownership separately.
The filing lists Vanguard’s principal office at 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Positive
- None.
Negative
- None.
FAQ
What does Vanguard report for RGEN ownership in this Schedule 13G/A amendment?
The filing states 0 shares beneficially owned and 0% of the class. It also reports 0 voting and dispositive power as of the amendment's disclosure.
Why did The Vanguard Group change its reporting in the RGEN filing?
Vanguard cites an internal realignment on January 12, 2026 under SEC Release No. 34-39538, causing certain subsidiaries to report ownership separately from The Vanguard Group, Inc.
Who signed the RGEN Schedule 13G/A Amendment No. 7 for Vanguard?
The filing is signed by Ashley Grim, Head of Global Fund Administration, and dated 03/27/2026, representing Vanguard's attestation on the reported ownership.
Where is Vanguard’s principal business address listed in the RGEN amendment?
The Schedule 13G/A lists The Vanguard Group's principal office as 100 Vanguard Blvd., Malvern, PA, 19355 in the filing's contact information.